418 related articles for article (PubMed ID: 31023626)
1. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Pandyra AA; Mullen PJ; Goard CA; Ericson E; Sharma P; Kalkat M; Yu R; Pong JT; Brown KR; Hart T; Gebbia M; Lang KS; Giaever G; Nislow C; Moffat J; Penn LZ
Oncotarget; 2015 Sep; 6(29):26909-21. PubMed ID: 26353928
[TBL] [Abstract][Full Text] [Related]
3. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract][Full Text] [Related]
4. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
5. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.
Pandyra A; Mullen PJ; Kalkat M; Yu R; Pong JT; Li Z; Trudel S; Lang KS; Minden MD; Schimmer AD; Penn LZ
Cancer Res; 2014 Sep; 74(17):4772-82. PubMed ID: 24994712
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis.
Zhang T; Bai R; Wang Q; Wang K; Li X; Liu K; Ryu J; Wang T; Chang X; Ma W; Bode AM; Xia Q; Song Y; Dong Z
Cancer Prev Res (Phila); 2019 Dec; 12(12):837-848. PubMed ID: 31554629
[TBL] [Abstract][Full Text] [Related]
7. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
[TBL] [Abstract][Full Text] [Related]
8. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
9. Endogenous sterol intermediates of the mevalonate pathway regulate HMGCR degradation and SREBP-2 processing.
Chen L; Ma MY; Sun M; Jiang LY; Zhao XT; Fang XX; Man Lam S; Shui GH; Luo J; Shi XJ; Song BL
J Lipid Res; 2019 Oct; 60(10):1765-1775. PubMed ID: 31455613
[TBL] [Abstract][Full Text] [Related]
10. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
Maciejak A; Leszczynska A; Warchol I; Gora M; Kaminska J; Plochocka D; Wysocka-Kapcinska M; Tulacz D; Siedlecka J; Swiezewska E; Sojka M; Danikiewicz W; Odolczyk N; Szkopinska A; Sygitowicz G; Burzynska B
BMC Biotechnol; 2013 Aug; 13():68. PubMed ID: 24128347
[TBL] [Abstract][Full Text] [Related]
11. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer.
Longo J; Hamilton RJ; Masoomian M; Khurram N; Branchard E; Mullen PJ; Elbaz M; Hersey K; Chadwick D; Ghai S; Andrews DW; Chen EX; van der Kwast TH; Fleshner NE; Penn LZ
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):630-637. PubMed ID: 32203069
[TBL] [Abstract][Full Text] [Related]
12. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Longo J; Pandyra AA; Stachura P; Minden MD; Schimmer AD; Penn LZ
Mol Oncol; 2020 Oct; 14(10):2533-2545. PubMed ID: 32749766
[TBL] [Abstract][Full Text] [Related]
13. Statins and prostate cancer-hype or hope? The biological perspective.
Longo J; Freedland SJ; Penn LZ; Hamilton RJ
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):650-656. PubMed ID: 35768578
[TBL] [Abstract][Full Text] [Related]
14. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.
Goard CA; Chan-Seng-Yue M; Mullen PJ; Quiroga AD; Wasylishen AR; Clendening JW; Sendorek DH; Haider S; Lehner R; Boutros PC; Penn LZ
Breast Cancer Res Treat; 2014 Jan; 143(2):301-12. PubMed ID: 24337703
[TBL] [Abstract][Full Text] [Related]
15. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S
Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.
Li X; Chen YT; Josson S; Mukhopadhyay NK; Kim J; Freeman MR; Huang WC
PLoS One; 2013; 8(8):e70987. PubMed ID: 23951060
[TBL] [Abstract][Full Text] [Related]
17. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
Osaki Y; Nakagawa Y; Miyahara S; Iwasaki H; Ishii A; Matsuzaka T; Kobayashi K; Yatoh S; Takahashi A; Yahagi N; Suzuki H; Sone H; Ohashi K; Ishibashi S; Yamada N; Shimano H
Biochem Biophys Res Commun; 2015 Oct; 466(3):536-40. PubMed ID: 26381177
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines.
Irie N; Mizoguchi K; Warita T; Nakano M; Sasaki K; Tashiro J; Osaki T; Ishikawa T; Oltvai ZN; Warita K
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540310
[TBL] [Abstract][Full Text] [Related]
19. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
Dimitroulakos J; Marhin WH; Tokunaga J; Irish J; Gullane P; Penn LZ; Kamel-Reid S
Neoplasia; 2002; 4(4):337-46. PubMed ID: 12082550
[TBL] [Abstract][Full Text] [Related]
20. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.
Zhou Y; Tashiro J; Kamatani S; Irie N; Suzuki A; Ishikawa T; Warita K; Oltvai ZN; Warita T
Biochem Biophys Res Commun; 2023 Oct; 677():13-19. PubMed ID: 37541087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
